Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut segmented filamentous Bacteria impedes growth of B16F10 subcutaneous tumors via modulating T cell function.

Mucosal immunology·2026
Same author

Detection of Eosinophilic Cell-free Granules Based on Expression of CCR3 and MBP Markers in Colonic Biopsy of Pediatric Patients with Suspected and Confirmed Eosinophilic Colitis.

Iranian journal of immunology : IJI·2026
Same author

Soil-derived microbiota induces T regulatory cells and protect against mouse colitis, metabolic disease, and sepsis.

Gut microbes·2026
Same author

Retraction notice to "MiR-211 plays a dual role in cancer development: From tumor suppressor to tumor enhancer" [Cellular Signalling 101 (2023) 110504].

Cellular signalling·2024
Same author

Microbiome modulation in inflammatory diseases: Progress to microbiome genetic engineering.

Cancer cell international·2023
Same author

Machine learning models to predict surgical case duration compared to current industry standards: scoping review.

BJS open·2023

Related Experiment Video

Updated: Jul 12, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Improved Protocol for Establishing CD4+ Hybridomas Specific for Human Class II MHC/Peptide Complex.

Fatemehsadat Mousavinasab1, Edyta A Szurek1, Anna Cebula1

  • 1Institute for Biomedical Sciences, Center for Translational Immunology, Georgia State University, Atlanta, GA, USA.

Bio-Protocol
|July 10, 2026
PubMed
Summary

Researchers improved a mouse model to better study autoimmune diseases like type 1 diabetes and celiac disease. This enhanced model accurately tracks T-cell responses to HLA-DQ8, a key genetic factor in these conditions.

Keywords:
Antigen-specific T cellsGenetic manipulationHLA-DQ8Human CD4Humanized miceT-cell hybridoma

More Related Videos

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Related Experiment Videos

Last Updated: Jul 12, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Area of Science:

  • Immunology
  • Genetics

Background:

  • Autoreactive CD4+ T cells play a crucial role in autoimmune diseases.
  • HLA-DQ8 is a significant genetic risk factor for type 1 diabetes and celiac disease.
  • Understanding HLA-DQ8's influence on T-cell responses is vital for developing treatments.

Purpose of the Study:

  • To investigate how HLA-DQ8 shapes the autoreactive CD4+ T-cell repertoire.
  • To overcome limitations in existing mouse models for studying human HLA-DQ8-restricted T-cell responses.
  • To develop an improved hybridoma system for accurate assessment of T-cell signaling.

Main Methods:

  • Generated T-cell hybridomas from HLA-DQ8 humanized mice using a modified BW5147 Nur77-GFP (BW-GFP) platform.
  • Engineered a BW-GFP fusion partner with optimized human CD4 (hCD4) to enhance CD4-HLA-DQ8 interactions.
  • Compared responses of hybridomas with and without hCD4 to HLA-DQ8/peptide complexes.

Main Results:

  • The modified BW-GFP platform with hCD4 demonstrated enhanced responses of CD4+ T cells to HLA-DQ8/peptide complexes.
  • This improvement was observed in both regulatory (Treg) and conventional (non-Treg) CD4+ T cells.
  • The engineered system showed improved reactivity and physiological accuracy in screening T-cell responses.

Conclusions:

  • The optimized hCD4-BW-GFP system enhances CD4-HLA class II compatibility in HLA-DQ8 humanized hybridoma models.
  • This improved system accurately reflects HLA-DQ8-restricted autoimmunity.
  • The approach is adaptable for studying other HLA-transgenic mouse models and self/foreign antigens.